Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies
- 6 August 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 17 (9) , 609-616
Abstract
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by low platelets and an increased risk of bleeding. Platelet autoantibodies target major platelet glycoproteins and cause Fc-mediated platelet destruction in the spleen and reticuloendothelial systems. As markers of disease, platelet autoantibodies are important therapeutic targets. Neonatal Fc receptor (FcRn) antagonists are a new class of therapeutics that reduce the half-life of immunoglobulin G including platelet autoantibodies. Spleen tyrosine kinase (Syk) inhibitors interfere with Fc-mediated platelet clearance. Bruton's tyrosine kinase (BTK) inhibitors, and inhibitors of B-cell activating factor (BAFF) reduce antibody production. The efficacy of these targeted therapies emphasize the role of platelet autoantibodies in ITP even though they can be difficult to detect. This review includes an in-depth exploration of the pathophysiologic mechanisms of ITP, focusing on autoantibodies. Treatments outlined in this review include a) FcRn antagonists (efgartigimod), b) complement inhibitors (sutimlimab), c) B-cell directed therapies such as BTK inhibitors (rilzabrutinib), anti-BAFF agents (belimumab, ianalumab), and Syk inhibitors (fostamatinib, sovleplenib), d) plasma-cell directed therapies (daratumumab, bortezomib), and e) cellular therapeutic products. Platelet antibodies are often elusive in ITP; yet novel treatments targeting this pathway reinforce their role in the pathogenesis of this autoimmune platelet disorder.Keywords
This publication has 66 references indexed in Scilit:
- Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune DiseasesArthritis & Rheumatology, 2023
- Changing Paradigms in ITP Management: Newer Tools for an Old DiseaseTransfusion Medicine Reviews, 2022
- Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectivesAnnals of Hematology, 2022
- Recent advances in the mechanisms and treatment of immune thrombocytopeniaEBioMedicine, 2022
- Response to rituximab in children and adults with immune thrombocytopenia (ITP)Research and Practice in Thrombosis and Haemostasis, 2021
- Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical featuresResearch and Practice in Thrombosis and Haemostasis, 2020
- Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAmerican Journal of Hematology, 2019
- Next-generation Fc receptor–targeting biologics for autoimmune diseasesAutoimmunity Reviews, 2019
- Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial programAmerican Journal of Hematology, 2019
- Thrombopoietin and Platelet Production in Chronic Immune ThrombocytopeniaHematology/Oncology Clinics of North America, 2009